In This Section

CICR Steering Committee

Andrew J. Phillips, PhD
Chairperson

Andrew J. Phillips, PhD

(2019-2020)

President and Chief Scientific Officer
C4 Therapeutics
Cambridge, Massachusetts

Philip Jones, PhD
Chairperson-elect

Philip Jones, PhD

(2019-2020)

Vice President, Therapeutics Discovery, and Head of Drug Discovery
UT MD Anderson Cancer Center
Houston, Texas

Julian Blagg, DPhil
Past Chairperson

Julian Blagg, DPhil

(2019-2020)

Vice President, Drug Discovery
NeoPhore & Azeria Therapeutics
Cambridge, United Kingdom

Julian Adams, PhD

Julian Adams, PhD

(2018-2020)

CEO and Chairman
Gamida-Cell
Cambridge, Massachusetts

James E. Audia, PhD

James E. Audia, PhD

(2019-2021)

Visiting Scholar, Northwestern University
Head of Medicinal Chemistry and Senior Advisor, Karuna Therapeutics
Entrepreneur-in Residence, Third Rock Ventures

James R. Bischoff, PhD

James R. Bischoff, PhD

(2018-2020)

Global Head Targeted Therapy-Oncology
Roche Applied Science
Basel, Switzerland

Michael Brands, Dr.Rer.Nat

Michael Brands, Dr.Rer.Nat

(2018-2020)

Senior Vice President Drug Discovery-Small Molecule Innovation
Bayer Pharma AG
Berlin, Germany

Sara J. Buhrlage, PhD

Sara J. Buhrlage, PhD

(2018-2020)

Assistant Professor of Biological Chemistry and Molecular Pharmacology
Dana-Farber Cancer Institute
Boston, Massachusetts

Ivan Cornella-Taracido, PhD

Ivan Cornella-Taracido, PhD

(2019-2021)

Vice President, Proteomics and Chemical Biology
Cedilla Therapeutics
Cambridge, Massachusetts

Chudi O. Ndubaku, PhD

Chudi O. Ndubaku, PhD

(2019-2021)

Vice President, Drug Discovery
ORIC Pharmaceuticals
South San Francisco, California

Xiaojing (Gina) Wang

Xiaojing (Gina) Wang

(2019-2021)

Principal Scientist and Project Team Lead
Genentech, Inc.
South San Francisco, California